Q1 2024 · 13F-HR
Darwin Global Management, Ltd.holdings as filed
Filed 2024-05-15 · accession 0001892688-24-000066
$751.2M
Reported value
12
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 92243G108 | PCVX | VAXCYTE INC | $187.9M | 25.0% | 2,750,804 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $107.9M | 14.4% | 1,436,964 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $95.1M | 12.7% | 1,435,950 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $80.8M | 10.8% | 1,476,974 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $78.6M | 10.5% | 1,982,016 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $70.0M | 9.32% | 2,119,598 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $55.3M | 7.36% | 832,198 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $24.6M | 3.27% | 1,109,650 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $17.9M | 2.39% | 473,200 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $12.0M | 1.59% | 2,332,928 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $10.6M | 1.42% | 465,000 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $10.5M | 1.40% | 79,600 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.